These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22571701)

  • 21. Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?
    Oran B
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S43-9. PubMed ID: 26297277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research.
    Verneris MR; Lee SJ; Ahn KW; Wang HL; Battiwalla M; Inamoto Y; Fernandez-Vina MA; Gajewski J; Pidala J; Munker R; Aljurf M; Saber W; Spellman S; Koreth J
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1783-9. PubMed ID: 26055300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
    Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic cell transplantation in pediatric patients with acute leukemias or myelodysplastic syndrome using unrelated adult or umbilical cord blood donors in Brazil.
    Tavares RCB; Bonfim CS; Seber A; Pereira Lermontov S; Coulturato V; Zecchin VG; Ribeiro L; Fernandes JF; Daudt LE; Grecco CS; Darrigo-Jr LG; Villela N; Nichele S; Gouveia R; Bouzas LF; Hamerschlak N; Vigorito AC; da Silva PM; da Silva PO; da Silva CC; de Souza Fernandez C; Flowers ME; Arcuri LJ
    Pediatr Transplant; 2020 Nov; 24(7):e13789. PubMed ID: 32757316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS).
    Deeg HJ
    Hematology Am Soc Hematol Educ Program; 2005; ():167-73. PubMed ID: 16304376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transplant strategies for patients with myelodysplastic syndromes.
    Deeg HJ
    Curr Opin Hematol; 2006 Mar; 13(2):61-6. PubMed ID: 16456370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemopoietic cell transplantation for the myelodysplastic syndromes.
    Scott BL; Deeg HJ
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):297-307. PubMed ID: 16088314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antithymocyte globulin improves the survival of patients with myelodysplastic syndrome undergoing HLA-matched unrelated donor and haplo-identical donor transplants.
    Wang H; Liu H; Zhou JY; Zhang TT; Jin S; Zhang X; Chen SN; Li WY; Xu Y; Miao M; Wu DP
    Sci Rep; 2017 Mar; 7():43488. PubMed ID: 28262717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
    Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
    Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hematopoietic cell transplantation (HCT) in MDS patients of older age.
    Niederwieser C; Kröger N
    Leuk Lymphoma; 2024 May; 65(5):570-584. PubMed ID: 38315612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hematopoietic cell transplantation for myelodysplastic syndrome.
    Deeg HJ
    Am Soc Clin Oncol Educ Book; 2015; ():e375-80. PubMed ID: 25993199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.
    Castro-Malaspina H; Jabubowski AA; Papadopoulos EB; Boulad F; Young JW; Kernan NA; Perales MA; Small TN; Hsu K; Chiu M; Heller G; Collins NH; Jhanwar SC; van den Brink M; Nimer SD; O'Reilly RJ
    Biol Blood Marrow Transplant; 2008 Apr; 14(4):458-68. PubMed ID: 18342789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemopoietic cell transplantation for myelodysplastic syndromes.
    Benesch M; Deeg HJ
    Curr Hematol Rep; 2003 May; 2(3):209-16. PubMed ID: 12901342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
    Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome.
    de Witte T; Oosterveld M; Muus P
    Blood Rev; 2007 Jan; 21(1):49-59. PubMed ID: 16822600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
    Demuynck H; Verhoef GE; Zachee P; Emonds MP; van der Schueren E; van den Berghe H; Vandenberghe P; Casteels-Van Daele M; Boogaerts MA
    Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic hematopoietic cell transplantation: the state of the art.
    Gyurkocza B; Rezvani A; Storb RF
    Expert Rev Hematol; 2010 Jun; 3(3):285-99. PubMed ID: 20871781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolution of hematopoietic SCT in myelodysplastic syndrome.
    Kindwall-Keller T; Isola LM
    Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy.
    Zimmerman Z; Scott BL; Gopal AK; Sandmaier BM; Maloney DG; Deeg HJ
    Bone Marrow Transplant; 2012 Jun; 47(6):804-9. PubMed ID: 21909142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.